Access
All Things Nuclear

Portland Holdings Is guided by our MANTRA of

Doing Well, By Doing Good

 

Portland Holdings' interest in All Things Nuclear aims to address two of humankinds' unmet needs: Cancer and Clean Energy.

Portland Holdings is committed to urging governments and industries toward a net-zero carbon future by investing in companies that harness the potential of nuclear energy and nuclear medicine.

Portland Holdings sees the urgency and it is responding.


Media

MLC Portrait

BNN: Billionaire Michael Lee-Chin on investing in nuclear power

Michael Lee-Chin, businessman, investor and philanthropist, joins BNN Bloomberg to discuss his journey in investing in renewable energy.
Read More
MLC Portrait

WP: Why Michael Lee-Chin is investing in nuclear power

Billionaire advisor and entrepreneur says the same principles that he used to build his wealth have dictated a focus on nuclear energy
Read More
MLC Portrait

WP: Why Michael Lee-Chin collaborated with MBM Holding of Dubai

Billionaire investor, and former advisor, outlines why he’s working with the Emirati holding company, and what that should mean for advisors
Read More
ITM Logo

ITM Announces Plans To Expand Radioisotope Production Capacities

ITM Isotope Technologies Munich secures a €255 million equity investment supporting the development of its oncology pipeline, expanding manufacturing capacities, and improving global access to radiopharmaceuticals.
Read More

MAKING STRIDES IN ALL THINGS NUCLEAR

 
Portland Holdings Path to All Things Nuclear
CNL and AIC Global Holdings Inc., a subsidiary of Portland Holdings Inc., sign MOU to address the world’s climate and health challenges
MEMORANDUM OF UNDERSTANDING WITH

CANADIAN NUCLEAR LABORATORIES


Under the terms of the Memorandum of Understanding, Canadian Nuclear Laboratories (CNL) will contribute scientific and technological knowledge and capabilities, and Portland Holdings group of companies will provide business expertise and funding support for opportunities jointly developed by the parties. The collaborative effort will center on long term solutions for the decarbonization of global economies and the development of radiopharmaceuticals to combat cancer.

MEMORANDUM OF Understanding With

MBM Holding

Portland Holdings Investco Limited and MBM Holding have announced a memorandum of understanding to collaborate on co-investments and partnerships in various areas including nuclear medicine, targeted radionuclide therapy (TRT), and nuclear and renewable energy. The collaboration is in alignment with the vision of his Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, which is to contribute to Dubai's economic development, while also addressing global challenges such as rising cancer incidence rates and the need for sustainable energy solutions.

All Things Nuclear SCIENTIFIC Team

 
Christopher Deir

Chief Nuclear Officer, AIC Global Holdings Inc.

With over 25 years in the Canadian nuclear power industry, Chris brings a wide range of experiences in the development, deployment and operation of nuclear facilities. His current role as Chief Nuclear...

Read More

Officer of AIC Global Holdings Inc. builds on a career that encompasses many facets, including most recently managing Ontario Power Generation (OPG)’s engagements with customers related to the deployment of small modular reactors (SMR) and developing peer utility relationships between OPG and other nuclear utilities within Canada and globally. Chris worked as a member of the Generation mPower LLC’s team on the advancement of the mPower SMR designed by Babcock & Wilcox for its deployment in Canada as well as leading Hitachi Canada Ltd.’s business development activities in the Canadian nuclear market. With a master’s degree in nuclear engineering, Chris joined Atomic Energy of Canada Limited as a design engineer for the CANDU product line which led to increasing roles of responsibility as part of the restart efforts of nuclear reactors at both Pickering and Bruce Power. Chris has served as a member of the Board of Directors of the Organization of Canadian Nuclear Industries.

Dr. Hubert Walinski

Chief Scientific Officer, Life Sciences, AIC Global Holdings Inc.

Dr. Walinski brings over 13 years of experience in the pharmaceutical and biotech sector with expertise across different therapeutic areas.

Read More

Previously, Dr. Walinski was the Head of Medical at AstraZeneca Canada where he was responsible for continued success of the Respiratory and Immunology portfolio, as well expansion into the infectious disease and vaccine departments.

He graduated with an Honours B.Sc. in Biology with a minor in Biochemistry from the McMaster University and obtained his Ph.D. from the University of British Columbia.

Dr. Ramon Arscott

Chief Medical Officer, AIC Global Holdings Inc.

As a Rhodes Scholar at the University of Oxford, Dr. Arscott completed a PhD (D.Phil) in Clinical Medicine (Tumor Immunology), researching immunology-based strategies for...

Read More

melanoma treatment. In addition to his contributions to research, Dr. Arscott also completed general surgery training at Harvard (Brigham and Women’s Hospital) before going on to complete the Harvard Combined Plastic Surgery Residency, culminating in being double-board-certified by the American Board of Surgery and the American Board of Plastic Surgery respectively.

Dr. Randy Peterson

International Business Development, Manager, AIC Global Holdings Inc.

Dr. Peterson has a combined 18 years of experience in business development and scientific advisor roles in the pharmaceutical, biopharmaceutical, and cell...

Read More

& gene therapy fields. His expertise focuses on commercialization pathways for novel therapeutics from discovery and venture establishment, to commercialization strategy. A particular area of expertise is cGMP manufacturing, process development, and Chemistry Manufacturing Controls (CMC) activities. Dr. Peterson has been involved in multiple IND manufacturing projects and contributed to multiple IND submissions.

Dr. Peterson obtained his Hons. BSc. (Co-op) Biology with specialization in Molecular biology & Biotechnology from the University of Waterloo, Ph.D. from McMaster University and MBA from the Goodman School of Business.

LEARN ABOUT PORTLAND INVESTMENT COUNSEL’S
INVESTMENT Products in the "All Things Nuclear space":

Portland Life Sciences Alternative Fund Portland Replacement of Fossil Fuels Alternative Fund

All Things Nuclear Newsletters

All Things Nuclear Academy

 

The Impact of Increased Nuclear Generation on the Existing Uranium Supply System

Join nuclear experts Chris Deir and Paul Thompson in this session of the All Things Nuclear series as they unravel the intricacies of nuclear energy. Gain insights into the uranium fuel cycle's significance, explore the impact of increased nuclear generation on the supply system, and discover the transformative potential of advanced nuclear SMRs, including strategies to reduce reliance on Russia's nuclear industry and bolster global energy security.

Beyond Conventional Decarbonization

This session of the All Things Nuclear series features a discussion with Chris Deir, Chief Nuclear Officer, AIC Global Holdings Inc on the possibilities of nuclear energy for decarbonization beyond conventional methods and how nuclear power can drive decarbonization efforts across industries.

Advancing Nuclear Solutions

This session of the All Things Nuclear series features a discussion with Chris Deir, Chief Nuclear Officer, AIC Global Holdings Inc. where we explore: Global warming, the impact of climate change and insights from the COP28 and beyond in tackling climate change.

An Introduction to Precision Oncology - Part One

In this session in the All Things Nuclear series, Dr. Hubert Walinski, the Chief Scientific Officer, Life Sciences, AIC Global Holdings Inc. provides an introduction to precision oncology; how it works, how it evolved, some of the different modalities and the advances in oncology therapies.

An Introduction to Precision Oncology - Part Two

In this session in the All Things Nuclear series, Dr. Randy Peterson, International Business Development Manager of AIC Global Holdings Inc. provides an overview of the different cancer treatment options and key success factors which can influence commercialization and potentially increase adoption of these innovative therapies.

An Introduction to Precision Oncology - A Practitioner’s View

In this session in the All Things Nuclear series, Dr. Ramon Arscott, Chief Medical Officer of AIC Global Holdings Inc. provides insights from a practitioner’s perspective on the current clinic approach to cancer treatment and how precision oncology looks to improve and disrupt the longstanding clinical paradigm and approach to cancer treatment.

A New Era of Radiopharmaceuticals

In this session in the All Things Nuclear series, Dr. Hubert Walinski, the Chief Scientific Officer, Life Sciences, AIC Global Holdings Inc. discusses radiopharmaceuticals by providing insights into the radioisotope space and its future in terms of its potential to revolutionize the patient’s cancer journey.

Advancing to a Clean Energy Future

In this session in the All Things Nuclear series, Dr. Stephen Bushby, the former Chief Nuclear Officer of AIC Global Holdings Inc. discusses clean energy and its importance for our future. As we face the challenges of climate change, clean energy is becoming more important as a way to reduce greenhouse gas emissions and promote a sustainable future.

An Introduction to Nuclear Energy

In this session of the All Things Nuclear series, Dr. Stephen Bushby, the former Chief Nuclear Officer of AIC Global Holdings Inc. provides an introduction to different aspects of nuclear power including its history, science, safety, waste, and the potential future of nuclear energy.

Small Modular Reactors (SMRs): Revolutionizing the Nuclear Landscape

The development and deployment of SMRs is a growing trend in the nuclear industry, with potential benefits in terms of increased safety, flexibility, and cost-effectiveness. This panel discussion explores the advantages of SMRs, their potential contributions to the nuclear industry and energy sector, along with the challenges and opportunities associated with their development and deployment.